Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
Trial details
- Registry ID
- NCT06843239
- Drugs studied
- Tibulizumab
TrialRedline tracks 2 clinical trials sponsored by Zura Bio Inc: 2 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)NCT06843239 | Tibulizumab | Active not recruiting | 2027-05Estimated |
| Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefenseNCT06993610 | Tibulizumab Dose A, Tibulizumab Dose B | Active not recruiting | 2026-09-18Actual |
Names as written in the registry records.
NCT06993610 · Zura Bio Inc
Before: Estimated. After: Actual.
Before: 225 participants (planned). After: 247 participants (actual).
Before: Estimated. After: Actual.
Before: Nov 2026. After: 18 Sep 2026.
NCT06843239 · Zura Bio Inc
Before: Recruiting. After: Active not recruiting.
NCT06993610 · Zura Bio Inc
Before: Recruiting. After: Active not recruiting.
NCT06843239 · Zura Bio Inc
Before: Dec 2026. After: May 2027.
NCT06993610 · Zura Bio Inc
Before: 180 participants (planned). After: 225 participants (planned).
Before: Sep 2026. After: Nov 2026.
NCT06993610 · Zura Bio Inc
Before: 225 participants (planned). After: 180 participants (planned).
NCT06993610 · Zura Bio Inc
Before: 180 participants (planned). After: 225 participants (planned).